12 completed, 3 active not recruiting. 15 Phase 1.
By phase and status
Follow BI 456906: new trials by email Literature Review of BI 456906 trials Research Report on BI 456906
Trials (filtered) newest first · largest first
All 15 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity
Survodutide formulation A, Survodutide formulation B2 - Healthy, Obesity | Phase 1 | Active not recruiting | 44 | 2026-09-02 | 2026-10-28 |
A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector
Survodutide formulation A, Survodutide formulation B2 - Healthy, Obesity | Phase 1 | Completed | 56 | 2026-03-03 | 2026-06-15 |
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
Survodutide, Semaglutide - Obesity | Phase 1 | Active not recruiting | 64 | 2025-03-26 | 2026-05-12 |
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
BI 456906, Semaglutide - Obesity | Phase 1 | Active not recruiting | 29 | 2024-11-01 | 2026-09-09 |
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
Survodutide, Bupropion, Caffeine - Overweight, Obesity | Phase 1 | Completed | 34 | 2024-10-01 | 2026-03-13 |
A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems
BI 456906 - Healthy, Renal Impairment | Phase 1 | Completed | 42 | 2024-05-15 | 2026-03-13 |
A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity
BI 456906, BI 1820237, Placebo for BI 1820237 - Obesity | Phase 1 | Completed | 23 | 2024-04-30 | 2025-03-12 |
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity
BI 456906, Placebo to BI 456906, Moxifloxacin - Overweight, Obesity | Phase 1 | Completed | 110 | 2024-03-13 | 2026-03-13 |
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
BI 456906, Microgynon® - Healthy | Phase 1 | Completed | 32 | 2023-12-21 | 2025-04-16 |
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
BI 1820237, semaglutide, Placebo - Healthy, Obesity | Phase 1 | Completed | 88 | 2023-04-11 | 2025-01-22 |
A Study in Healthy Men to Test How BI 456906 is Processed in the Body
BI 456906 (C-14) - Healthy | Phase 1 | Completed | 6 | 2022-07-04 | 2022-12-14 |
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906
BI 456906 - Healthy, Liver Diseases | Phase 1 | Completed | 82 | 2022-04-27 | 2024-08-15 |
A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2
BI 456906, Placebo - Healthy | Phase 1 | Completed | 37 | 2020-06-01 | 2021-01-26 |
A Study to Test Different Doses of BI 456906 in Patients With Obesity
BI 456906, Placebo - Obesity | Phase 1 | Completed | 131 | 2018-07-26 | 2021-03-22 |
Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers
BI 456906, Placebo - Healthy | Phase 1 | Completed | 20 | 2017-06-30 | 2018-07-16 |
Conditions studied
Obesity (10) · Overweight (2) · Liver Diseases (1) · Renal Insufficiency (1)
Sponsors
Boehringer Ingelheim (15)
Countries
Germany (10) · Netherlands (2) · United States (2) · Belgium (1) · Hungary (1) · Japan (1) · New Zealand (1) · Poland (1) · Slovakia (1)
Results publications
PMID 36527386, PMID 38857788
NIH funding
2023 (3), 2017 (1), 2018 (1)